University Hospitals in US to conduct coronavirus clinical trials
University Hospitals in Cleveland, US is set to conduct two clinical trials of remdesivir to treat adult Covid-19 patients hospitalised
Tag: Clinical trial
Hundreds of Virus Patients Allowed to Try Gilead’s Ebola Drug
Hundreds of coronavirus patients have been treated with Gilead’s experimental Ebola treatment under an FDA program to allow access to
CycloLab picks up the gauntlet to fight coronavirus
The novel coronavirus SARS-CoV-2 is affecting 65 countries and territories around the world with almost 90,000 reported cases and almost
Gilead Sciences Initiates Two Phase 3 Studies of Investigational SBECD-enabled Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of
Oculis aces the Phase 2 clinical trial for OCS-01 treating DME
Oculis reported positive results from Phase 2 clinical studies of OCS-01 for treating DME
Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Marinus Data from SBECD-enabled Ganaxolone Phase 2 Trial in Refractory Status Epilepticus
Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated presented positive results from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
Oculis started Phase II clinical trial with OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced